OPINION AND ORDER
Jack Harold Jones, Don W. Davis, Alvin Bernal Jackson, Kenneth Dewayne Williams, Stacey Eugene Johnson, Jason Farrell McGehee, and Bruce Ward
I.
Rule 59(e) motions serve the limited function of correcting manifest errors of law or fact or to present newly discovered evidence.
United States v. Metro. St. Louis Sewer Dist.,
The new evidence presented by the plaintiffs includes an article from the Texarkana Gazette, which attributes to Dina Tyler, Public Information Officer for the ADC, a statement that the MEA allows the Department of Correction “flexibility in case one of the chemicals used in lethal injections became unavailable, was improved or a more effective substitute emerged.” This flexibility, according to the article, would allow executions to proceed, instead of having to be stayed until the Legislature changed the protocol. The article also states that Tyler “said the department provides information about the drugs and procedures for execution to each death row inmate.” The article does not state that there is a high likelihood that the protocol will in fact be changed prior to the execution of any of the plaintiffs in this action. The article does not support the plaintiffs’ allegations that the lethal injection protocol might be changed under circumstances in which they could not discover and challenge the changed protocol.
The plaintiffs also offer an article from an Ohio newspaper discussing a worldwide shortage of the anesthetic used in lethal injections. However, the article does not suggest that the ADC is without the anes
In summary, the newly discovered evidence does not show that it is likely that the protocol will be changed before execution of any of the plaintiffs or that the plaintiffs would be prevented from learning of any such change, if one occurs. Even if the complaints were amended to include the information in the two news articles, the complaints would still fail to raise the right to relief above a speculative level and therefore would still fail to state a claim upon which relief may be granted.
Bell Atlantic Corp. v. Twombly,
II.
As mentioned, McGehee and Ward contend that the ADC violates the Food, Drug and Cosmetic Act (“FDCA”), 21 U.S.C. §§ 301 et seq., as well as the Controlled Substances Act (“CSA”), 21 U.S.C. §§ 801 et seq. The Court granted McGehee’s and Ward’s motions to intervene in the same order in which the Court dismissed all of the plaintiffs’ complaints for failure to state a claim, but the Court failed to address McGehee’s and Ward’s claims that the ADC violates the FDCA and the CSA.
The complaints by McGehee and Ward allege four counts that are relevant to the present issue. Count 3 alleges that the FDCA forbids the administration of any dangerous drug without a prescription by a practitioner who is licensed by law to administer such drugs, citing 21 U.S.C. § 353. Count 3 then alleges that the ADC does not have or intend to obtain a valid prescription for the drugs that would be used in an execution by lethal injection. Count 4 alleges that the FDCA requires that drugs obtained through interstate commerce be approved by the FDA for their intended use, citing 21 U.S.C. § 355. Count 4 then alleges that the drug or drugs that the ADC intends to use in execution by lethal injection have not been approved by the FDA for that use. Count 5 alleges that the CSA forbids the administration of any controlled substance without a valid prescription, citing 21 U.S.C. § 829(b). Count 5 then alleges that the ADC intends to use in lethal injection one or more controlled substances and does not have a valid prescription for those controlled substances. Count 6 alleges that the CSA requires that any person who dispenses or proposes to dispense a controlled substance must obtain a registration from the Attorney General permitting him to do so, citing 21 U.S.C. § 822. Count 6 then alleges that the ADC intends or proposes to dispense one or more controlled substances during execution without obtaining registration from the Attorney General. In their prayers for relief, McGehee and Ward request that the Court declare that the defendants are violating or threatening to violate the FDCA and the CSA and, in addition, that the Court grant a permanent injunction pursuant to 28 U.S.C. § 2202 barring execution under the MEA and in violation of the FDCA or CSA.
The district courts of the United States have jurisdiction to enjoin violations of the FDCA. 21 U.S.C. § 332. Except for actions by a state to enforce specified sections of the FDCA, all proceedings to enforce or to restrain violations of the FDCA must be brought by and in the name of the United States. 21 U.S.C. § 337. Thus, the FDCA does not provide for a private right of action to enforce its provisions.
See Buckman Co. v. Plaintiffs’ Legal Comm.,
McGehee and Ward do not contend that the FDCA or the CSA creates a private right of action. Instead, they argue that a court may entertain a suit seeking a declaration that the ADC has violated or will violate those statutes even though Congress provided for no private right of action under either of them.
Two district courts and one court of appeals have addressed the issue. The Western District of Missouri held that inmates facing death by lethal injection may bring an action pursuant to the Declaratory Judgment Act seeking a declaration that the state’s lethal injection protocol violates the FDCA and the CSA even though those statutes create no private right of action.
Ringo v. Lombardi,
McGehee and Ward’s argument that a party without a private right of action may nevertheless seek a declaratory judgment is based largely on the opinion in
Franklin v. Massachusetts,
For purposes of establishing standing, however, we need not decide whether injunctive relief against the President was appropriate, because we conclude that the injury alleged is likely to be redressed by declaratory relief against the Secretary alone. See Duke Power Co. v. Carolina Environmental Study Group, Inc.,438 U.S. 59 , 75, n. 20,98 S.Ct. 2620 , 2631, n. 20,57 L.Ed.2d 595 (1978); Allen v. Wright, [468 U.S. 737 , 752,104 S.Ct. 3315 , 3325,82 L.Ed.2d 556 (1984) ]. The Secretary certainly has an interest in defending her policy determinations concerning the census; even though she cannot herself change the reapportionment, she has an interest in litigating its accuracy. And, as the Solicitor General has not contended to the contrary, we may assume it is substantially likely that the President and other executive and congressional officials would abide by an authoritative interpretation of the census statute and constitutional provision by the District Court, even though they would not be directly bound by such a determination.
Id.
at 803,
The question in the case at bar is whether the reasoning of
Franklin
extends to a case in which Congress has enacted a statutory scheme but has not created a private right of action as an enforcement mechanism — in such a case, does
Franklin
authorize a district court to entertain a declaratory judgment action seeking a declaration that the statute has been or will be violated? This Court does not believe that
Franklin
reaches so far. The issue in
Franklin
was whether the plaintiffs had standing sufficient to create a case or controversy under Article III.
Id.
at 801,
The relevant part of the Declaratory Judgment Act provides:
In a case of actual controversy within its jurisdiction ... any court of the United States, upon the filing of an appropriate pleading, may declare the rights and other legal relations of any interested party seeking such declaration, whether or not further relief is or could be sought. Any such declaration shall have the force and effect of a final judgment or decree and shall be reviewable as such.
In
Merrell Dow Pharms., Inc. v. Thompson,
The significance of the necessary assumption that there is no federal private cause of action thus cannot be overstated. For the ultimate import of such a conclusion, as we have repeatedly emphasized, is that it would flout congressional intent to provide a private federal remedy for the violation of the federal statute.
Id.
at 812,
When we conclude that Congress has decided not to provide a particular federal remedy, we are not free to “supplement” that decision in a way that makes it “meaningless.” Cf. Mobil Oil Corp. v. Higginbotham,436 U.S. 618 , 625,98 S.Ct. 2010 , 2015,56 L.Ed.2d 581 (1978) (When Congress “does speak directly to a question, the courts are not free to ‘supplement’ Congress’ answer so thoroughly that the Act becomes meaningless”). See also California v. Sierra Club, 451 U.S. [287, 297,101 S.Ct. 1775 , 1781,68 L.Ed.2d 101 (1981) ] (“The federal judiciary will not engraft a remedy on a statute, no matter how salutary, that Congress did not intend to provide”).
Id.
at 812 n. 10,
The Supreme Court’s opinion in
Heckler v. Chaney,
Merrell Dow, Skelly, Schilling,
and
Heckler
lead to the conclusion that the Declaratory Judgment Act does not authorize actions to decide whether federal statutes have been or will be violated when no private right of action to enforce the statutes has been created by Congress. To entertain, under the auspices of the Declaratory Judgment Act, a cause of action brought by private parties seeking a declaration that the FDCA or the CSA has been violated would, in effect, evade the intent of Congress not to create private rights of action under those statutes and would circumvent the discretion entrusted to the executive branch in deciding how and when to enforce those statutes. Cf.
C & E Servs., Inc.,
The plaintiffs, citing 21 U.S.C. §§ 355(c)(3)(D)(i)(I) and (j)(5)(C)(i)(I), contend that Congress has expressly prohibited only a specific class of declaratory judgment suits concerning new and generic drugs. Those statutory provisions are part of the statutory scheme relating to approval of and patents for new and generic drugs. Congress has authorized actions for declaratory judgments pertaining to patents for new and generic drugs in certain circumstances. See 21 U.S.C. §§ 355(c)(3)(D)(i)(II), Cj)(5)(C)(i)(II) 2 (authorizing the filing of civil actions to obtain declaratory judgments under 28 U.S.C. § 2201 regarding the validity of patents for drugs for which applicants have sought approval). The two subsections to which the plaintiffs refer impose certain restrictions on such actions. Those subsections and the related provisions have nothing to do with enforcement of the provisions of the FDCA at issue here. It cannot reasonably be inferred from those provisions that Congress intended to allow a private right of action to enforce the FDCA in the context of a case such as this.
McGehee and Ward seek to bypass the congressionally mandated enforcement schemes for the FDCA and the CSA; in effect, they seek private enforcement of those statutes by means of a declaratory judgment. Congress committed complete
The remaining plaintiffs seek leave to amend their complaints to include claims that the ADC has violated or will violate the FDCA and the CSA. For the reasons stated, it would be futile to permit those amendments.
Owen v. Gen. Motors Corp.,
CONCLUSION
For the reasons stated, the motion to vacate the judgment pursuant to Rule 59(e) of the Federal Rules of Civil Procedure is DENIED. Document # 68.
Notes
. The full title of the MEA is "An Act to Clarify the Existing Procedures for Capital Punishment by Lethal Injection; and for Other Purposes.” 2009 Ark. Acts 1296. It is codified at Ark.Code Ann. § 5-4-617 (2009 Supp.).
. These provisions are explained more fully in
Mova Pharm. Corp. v. Shalala,
